Abstract: The present invention relates to an antiviral composition for Betacoronavirus comprising rhein and meclofenamic acid as active components. When the antiviral composition of the present invention is used, an antiviral effect is demonstrated whereby the viral RNA level of SARS-CoV-2 and HCoV-OC43 is suppressed, and thus it is possible to treat or prevent COVID-19 or a cold.

Abstract: The present invention relates to an RNA interactome capturing protocol and an antiviral composition discovered using same. When used, the antiviral composition and pharmaceutical composition of the present invention can effectively inhibit viral infection and suppress viral proliferation in vivo after viral infection.

Abstract: The present invention relates to a technology for preventing or treating virus infection and infectious disease by inducing a mixed tailing regarding an RNA virus.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising miR-324 and TUT4/7 expression modulators, wherein the pharmaceutical composition of the present invention can prevent cell division and hinder cancer development by inhibiting the function of TUT4/7, and can increase the amount of miR-324-5p and suppress the function of miR-324-3p.1, and therefore can be effectively used for prevention, treatment, or diagnosis of cancer.

Abstract: The present disclosure provides a new protocol for sequencing the 3? end of messenger RNA (mRNA). The present disclosure can be very favorably used in analyzing the repetitive sequences of nucleic acids, which are difficult to analyze by current sequencing methods, especially, homopolymeric sequences (poly[A] sequence) of mRNA. The present disclosure has significantly improved sensitivity to mRNA compared with an existing method, thereby obtaining a lot of genetic information from a small amount of sample. The method of the present disclosure reduces the time and cost for sequencing the 3? end of mRNA and can be applied to various samples, and thus, can be used as a useful tool in the study of RNA synthesis/degradation and protein production in association with all life phenomena, including embryogenesis, cancer, and neurotransmission.

Abstract: The present disclosure provides a new protocol for sequencing the 3? end of messenger RNA (mRNA). The present disclosure can be very favorably used in analyzing the repetitive sequences of nucleic acids, which are difficult to analyze by current sequencing methods, especially, homopolymeric sequences (poly[A] sequence) of mRNA. The present disclosure has significantly improved sensitivity to mRNA compared with an existing method, thereby obtaining a lot of genetic information from a small amount of sample. The method of the present disclosure reduces the time and cost for sequencing the 3? end of mRNA and can be applied to various samples, and thus, can be used as a useful tool in the study of RNA synthesis/degradation and protein production in association with all life phenomena, including embryogenesis, cancer, and neurotransmission.